Content by Lonza

The tailor-made comprehensive offering spans a diversified clinical and commercial portfolio of innovative modalities, including process intensification and drug product manufacturing

How two activation approaches support clinical-scale expansion of T cells.

Collaboration to support late-stage clinical development and potential commercialization

Lonza collaborates with a biotech innovator to advance a promising oncology drug candidate, bimiralisib

Long-term collaboration began in 2013 and enabled commercial approval and rapid uptake for ZYNTEGLO™ in 2022

Hugh White from Lonza introduces a nucleic acid separation system designed for modern, efficient research.

New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain

In this webinar, Stefanie Müthel and Jessica Fiege will discuss how electroporation using the latest technology boosts cell engineering research by optimizing T cell transfection at scale.

In this webinar, Scott Kelsey, Kevin Grady, and Christopher Hughes will highlight how angiogenesis and vascularized in vitro models accelerate drug development.

Learn how immunotoxicity studies can benefit from optimized macrophage differentiation and polarization.

Learn how visualizing angiogenesis in real time supports drug development.

New methods for deriving macrophages from induced pluripotent stem cells are easier to scale and provide more clinically relevant data.

In this webinar, Ethan Shelkey and Aurita Menezes will highlight key aspects in the design of cell-based assays.

The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex^® Biopark in Visp (CH).

CASGEVY^® is the first cell therapy based on the CRISPR/Cas9 technology, discoverers of which were awarded the Nobel Prize in Chemistry in 2020.